BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 11956600)

  • 1. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
    Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
    Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
    Kasimir-Bauer S; Mayer S; Bojko P; Borquez D; Neumann R; Seeber S
    Clin Cancer Res; 2001 Jun; 7(6):1582-9. PubMed ID: 11410494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use?
    Kasimir-Bauer S; Oberhoff C; Sliwinska K; Neumann R; Schindler AE; Seeber S
    Breast Cancer Res Treat; 2001 Sep; 69(2):123-32. PubMed ID: 11759818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of high-dose chemotherapy and monoclonal antibody in breast-cancer patients: a pilot trial to monitor treatment effects on disseminated tumor cells.
    Hempel P; Müller P; Oruzio D; Behr W; Brockmeyer C; Wochner M; Ehnle S; Riethmüller R; Schlimok G
    Cytotherapy; 2000; 2(4):287-95. PubMed ID: 12042038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare expression of target antigens for immunotherapy on disseminated tumor cells in breast cancer patients without overt metastases.
    Kasimir-Bauer S; Otterbach F; Oberhoff C; Schmid KW; Kimmig R; Seeber S
    Int J Mol Med; 2003 Dec; 12(6):969-75. PubMed ID: 14612976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
    Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease.
    Braun S; Hepp F; Sommer HL; Pantel K
    Int J Cancer; 1999 Feb; 84(1):1-5. PubMed ID: 9988223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients.
    Becker S; Becker-Pergola G; Fehm T; Wallwiener D; Solomayer EF
    Anticancer Res; 2005; 25(3B):2171-5. PubMed ID: 16158960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA.
    Vannucchi AM; Bosi A; Glinz S; Pacini P; Linari S; Saccardi R; Alterini R; Rigacci L; Guidi S; Lombardini L; Longo G; Mariani MP; Rossi-Ferrini P
    Br J Haematol; 1998 Dec; 103(3):610-7. PubMed ID: 9858208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
    Thurm H; Ebel S; Kentenich C; Hemsen A; Riethdorf S; Coith C; Wallwiener D; Braun S; Oberhoff C; Jänicke F; Pantel K
    Clin Cancer Res; 2003 Jul; 9(7):2598-604. PubMed ID: 12855636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of bone marrow micrometastases with sentinel lymph node status in early-stage breast cancer.
    Saha S; Ali S; Ghanem M; Soni M; Wiese D; Arora M; Singh T; Iddings D
    Ann Surg Oncol; 2009 Feb; 16(2):276-80. PubMed ID: 19050967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
    Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V
    Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
    Bozionellou V; Mavroudis D; Perraki M; Papadopoulos S; Apostolaki S; Stathopoulos E; Stathopoulou A; Lianidou E; Georgoulias V
    Clin Cancer Res; 2004 Dec; 10(24):8185-94. PubMed ID: 15623593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.
    Braun S; Kentenich C; Janni W; Hepp F; de Waal J; Willgeroth F; Sommer H; Pantel K
    J Clin Oncol; 2000 Jan; 18(1):80-6. PubMed ID: 10623696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients.
    Schulze R; Schulze M; Wischnik A; Ehnle S; Doukas K; Behr W; Ehret W; Schlimok G
    Bone Marrow Transplant; 1997 Jun; 19(12):1223-8. PubMed ID: 9208116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer.
    Benoy IH; Elst H; Philips M; Wuyts H; Van Dam P; Scharpé S; Van Marck E; Vermeulen PB; Dirix LY
    Br J Cancer; 2006 Mar; 94(5):672-80. PubMed ID: 16495933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer.
    Lilleby W; Nesland JM; Fosså SD; Torlakovic G; Waehre H; Kvalheim G
    Int J Cancer; 2003 Jan; 103(1):91-6. PubMed ID: 12455058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy.
    Drageset V; Nesland JM; Erikstein B; Skovlund E; Sommer H; Anker G; Wist E; Lundgren S; Bergh J; Kvalheim G
    Int J Cancer; 2006 Jun; 118(11):2877-81. PubMed ID: 16381016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.